Ubiquitin-conjugating enzyme UBE2C: Molecular biology, role in tumorigenesis, and potential as a biomarker

Zhonglin Hao, Hui Zhang, John Kenneth Cowell

Research output: Contribution to journalReview article

51 Citations (Scopus)

Abstract

Ubiquitin-conjugating enzyme 2C (UBE2C) participates in cell cycle progression and checkpoint control by targeted degradation of short-lived proteins. As a conjugating enzyme, it directs polyubiquitination to preferred lysine in the substrates. In addition to its well-known role in cyclin B destruction that is essential for exit from mitosis, UBE2C also plays an important role in mitotic spindle checkpoint control. Cells overexpressing UBE2C ignore the mitotic spindle checkpoint signals and lose genomic stability, which is a hallmark of cancer. UBE2C expression is upregulated upon malignant transformation, and amplification of UBE2C is often seen at the chromosome level in cancers in a manner similar to c-Myc, which is directly upstream of UBE2C. UBE2C levels are upregulated in a wide range of solid tumors and hematological malignancies. The level of expression correlates with the aggressiveness of the tumor. High UBE2C expression is predictive of poor survival and perhaps high risk for relapse. UBE2C immunochemistry may be integrated into the diagnosis of thyroid malignancy and gliomas. This minireview summarizes what is known about the function of UBE2C focusing on its role in the regulation of spindle assembly checkpoint, its part in tumorigenesis, and its potential as a tumor marker for various cancers.

Original languageEnglish (US)
Pages (from-to)723-730
Number of pages8
JournalTumor Biology
Volume33
Issue number3
DOIs
StatePublished - Jun 1 2012

Fingerprint

Ubiquitin-Conjugating Enzymes
Molecular Biology
Carcinogenesis
Biomarkers
M Phase Cell Cycle Checkpoints
Neoplasms
Cyclin B
Immunochemistry
Genomic Instability
Hematologic Neoplasms
Tumor Biomarkers
Cell Cycle Checkpoints
Mitosis
Glioma
Lysine
Thyroid Gland
Chromosomes

Keywords

  • Cancer
  • Checkpoint
  • Genomic instability
  • Prognosis
  • UBE2C

ASJC Scopus subject areas

  • Cancer Research

Cite this

Ubiquitin-conjugating enzyme UBE2C : Molecular biology, role in tumorigenesis, and potential as a biomarker. / Hao, Zhonglin; Zhang, Hui; Cowell, John Kenneth.

In: Tumor Biology, Vol. 33, No. 3, 01.06.2012, p. 723-730.

Research output: Contribution to journalReview article

@article{cb38c0ceefac41e9b5b8bbd40ef4d52f,
title = "Ubiquitin-conjugating enzyme UBE2C: Molecular biology, role in tumorigenesis, and potential as a biomarker",
abstract = "Ubiquitin-conjugating enzyme 2C (UBE2C) participates in cell cycle progression and checkpoint control by targeted degradation of short-lived proteins. As a conjugating enzyme, it directs polyubiquitination to preferred lysine in the substrates. In addition to its well-known role in cyclin B destruction that is essential for exit from mitosis, UBE2C also plays an important role in mitotic spindle checkpoint control. Cells overexpressing UBE2C ignore the mitotic spindle checkpoint signals and lose genomic stability, which is a hallmark of cancer. UBE2C expression is upregulated upon malignant transformation, and amplification of UBE2C is often seen at the chromosome level in cancers in a manner similar to c-Myc, which is directly upstream of UBE2C. UBE2C levels are upregulated in a wide range of solid tumors and hematological malignancies. The level of expression correlates with the aggressiveness of the tumor. High UBE2C expression is predictive of poor survival and perhaps high risk for relapse. UBE2C immunochemistry may be integrated into the diagnosis of thyroid malignancy and gliomas. This minireview summarizes what is known about the function of UBE2C focusing on its role in the regulation of spindle assembly checkpoint, its part in tumorigenesis, and its potential as a tumor marker for various cancers.",
keywords = "Cancer, Checkpoint, Genomic instability, Prognosis, UBE2C",
author = "Zhonglin Hao and Hui Zhang and Cowell, {John Kenneth}",
year = "2012",
month = "6",
day = "1",
doi = "10.1007/s13277-011-0291-1",
language = "English (US)",
volume = "33",
pages = "723--730",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Ubiquitin-conjugating enzyme UBE2C

T2 - Molecular biology, role in tumorigenesis, and potential as a biomarker

AU - Hao, Zhonglin

AU - Zhang, Hui

AU - Cowell, John Kenneth

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Ubiquitin-conjugating enzyme 2C (UBE2C) participates in cell cycle progression and checkpoint control by targeted degradation of short-lived proteins. As a conjugating enzyme, it directs polyubiquitination to preferred lysine in the substrates. In addition to its well-known role in cyclin B destruction that is essential for exit from mitosis, UBE2C also plays an important role in mitotic spindle checkpoint control. Cells overexpressing UBE2C ignore the mitotic spindle checkpoint signals and lose genomic stability, which is a hallmark of cancer. UBE2C expression is upregulated upon malignant transformation, and amplification of UBE2C is often seen at the chromosome level in cancers in a manner similar to c-Myc, which is directly upstream of UBE2C. UBE2C levels are upregulated in a wide range of solid tumors and hematological malignancies. The level of expression correlates with the aggressiveness of the tumor. High UBE2C expression is predictive of poor survival and perhaps high risk for relapse. UBE2C immunochemistry may be integrated into the diagnosis of thyroid malignancy and gliomas. This minireview summarizes what is known about the function of UBE2C focusing on its role in the regulation of spindle assembly checkpoint, its part in tumorigenesis, and its potential as a tumor marker for various cancers.

AB - Ubiquitin-conjugating enzyme 2C (UBE2C) participates in cell cycle progression and checkpoint control by targeted degradation of short-lived proteins. As a conjugating enzyme, it directs polyubiquitination to preferred lysine in the substrates. In addition to its well-known role in cyclin B destruction that is essential for exit from mitosis, UBE2C also plays an important role in mitotic spindle checkpoint control. Cells overexpressing UBE2C ignore the mitotic spindle checkpoint signals and lose genomic stability, which is a hallmark of cancer. UBE2C expression is upregulated upon malignant transformation, and amplification of UBE2C is often seen at the chromosome level in cancers in a manner similar to c-Myc, which is directly upstream of UBE2C. UBE2C levels are upregulated in a wide range of solid tumors and hematological malignancies. The level of expression correlates with the aggressiveness of the tumor. High UBE2C expression is predictive of poor survival and perhaps high risk for relapse. UBE2C immunochemistry may be integrated into the diagnosis of thyroid malignancy and gliomas. This minireview summarizes what is known about the function of UBE2C focusing on its role in the regulation of spindle assembly checkpoint, its part in tumorigenesis, and its potential as a tumor marker for various cancers.

KW - Cancer

KW - Checkpoint

KW - Genomic instability

KW - Prognosis

KW - UBE2C

UR - http://www.scopus.com/inward/record.url?scp=84863602520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863602520&partnerID=8YFLogxK

U2 - 10.1007/s13277-011-0291-1

DO - 10.1007/s13277-011-0291-1

M3 - Review article

C2 - 22170434

AN - SCOPUS:84863602520

VL - 33

SP - 723

EP - 730

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 3

ER -